IKAROS family zinc finger 5Genealiases: PEGASUS · THC7 · ZNFN1A5
Q-omics provides the consensus-scored IKZF5 profile across patient tissues and cancer cell-line models. IKZF5 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, IKZF5 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, IKZF5 RNA expression shows 20,732 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, THCA, and UVM as cancer lineages where IKZF5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IKZF5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IKZF5 survival associations across molecular data types. IKZF5 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IKZF5 RNA expression–survival associations across cancer types. High IKZF5 expression shows unfavorable associations in ACC and UVM, but favorable associations in KIRC, LUAD, LGG and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for IKZF5 RNA expression.
This table summarizes IKZF5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for IKZF5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IKZF5 shows lower tumor expression in THCA, LUSC, KICH, UCEC, LUAD and KIRP. The THCA box plot shows higher IKZF5 RNA expression in normal versus tumor tissue (log2 FC = −0.783, t-test p < 0.001).
This table shows molecular features associated with IKZF5 in patient tissues and cancer cell lines. In patient samples, IKZF5 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, IKZF5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Lymphoma.
